Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics
J Clin Psychiatry 2004;65(4):557-564
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: It is important to assess cardiovascular risk factors to properly verify the potential consequences of atypical antipsychotic-related weight gain. The objective of the present study was to evaluate whether 2 atypical antipsychotics differ regarding their impact on the cardiovascular disease risk profile compared with a reference group.
Method: We conducted a cross-sectional, multicenter study to assess anthropometric indices of obesity and to obtain a comprehensive fasting metabolic risk profile. Either risperidone or olanzapine had to be prescribed as the first and only antipsychotic for a minimum of 6 months. Patients were compared with a reference group of nondiabetic men. Data were collected from August 1999 to August 2001.
Results: Eighty-seven patients treated with olanzapine (N = 42) or risperidone (N = 45) were evaluated. Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2.01 ± 1.05 vs. 1.34 ± 0.65 mmol/L, p <= .05), lower high-density lipoprotein (HDL)-cholesterol levels (0.92 ± 0.17 vs. 1.04 ± 0.21 mmol/L, p <= .05), higher cholesterol/HDL-cholesterol ratios (5.62 ± 1.70 vs. 4.50 ± 1.44, p <= .05), higher apolipoprotein B levels (1.07 ± 0.35 vs. 0.92 ± 0.27 g/L, p <= .05), smaller low-density lipoprotein peak particle diameters (252.6 ± 4.1 vs. 255.2 ± 4.3 Å, p < .01), and higher fasting insulin concentrations (103.9 ± 67.6 vs. 87.5 ± 56.1 pmol/L, p <= .05) than risperidone-treated patients. Moreover, 33% of olanzapine-treated patients were carriers of 3 atherogenic features of the metabolic syndrome as opposed to a prevalence of only 11% of risperidone-treated patients.
Conclusion: These results suggest that olanzapine-treated patients are characterized by a more deteriorated metabolic risk factor profile compared with risperidone-treated patients. These observations raise concerns about the potential differential long-term deleterious effects of some antipsychotics, such as olanzapine, on cardiovascular health.